OBJECTIVE: To evaluate cyclin D1 expression in vestibular schwannoma and its relationship with histologic, clinical, and radiologic features. PATIENTS: Twenty-one patients with histologically confirmed vestibular schwannoma. INTERVENTION: Immunohistochemistry analysis was performed with anticyclin D1. Histopathologic features studied included Antoni pattern and nuclear and stromal degenerative changes. Clinical charts, audiometric data, and magnetic resonance imaging characteristics were reviewed. MAIN OUTCOME MEASURES: Cyclin D1 expression and its association with histologic, clinical, and radiologic findings. RESULTS: Cyclin D1 expression was found in 52% of cases. Cyclin D1 expression was more frequent in right-sided tumors (p = 0.02) and in tumors with nuclear degenerative changes (p < 0.0001). Patients with negative cyclin D1 expression had longer duration of deafness (p = 0.02) and higher 2,000-Hz hearing thresholds (p = 0.04) than cyclin D1+ patients. CONCLUSION: Cyclin D1 expression, present in nearly half of the cases, may play a role in the development of these tumors. Further studies are needed to fully understand the contributions of histopathologic and immunohistochemical factors to vestibular schwannoma biological activity.
OBJECTIVE: To evaluate cyclin D1 expression in vestibular schwannoma and its relationship with histologic, clinical, and radiologic features. PATIENTS: Twenty-one patients with histologically confirmed vestibular schwannoma. INTERVENTION: Immunohistochemistry analysis was performed with anticyclin D1. Histopathologic features studied included Antoni pattern and nuclear and stromal degenerative changes. Clinical charts, audiometric data, and magnetic resonance imaging characteristics were reviewed. MAIN OUTCOME MEASURES: Cyclin D1 expression and its association with histologic, clinical, and radiologic findings. RESULTS:Cyclin D1 expression was found in 52% of cases. Cyclin D1 expression was more frequent in right-sided tumors (p = 0.02) and in tumors with nuclear degenerative changes (p < 0.0001). Patients with negative cyclin D1 expression had longer duration of deafness (p = 0.02) and higher 2,000-Hz hearing thresholds (p = 0.04) than cyclin D1+ patients. CONCLUSION:Cyclin D1 expression, present in nearly half of the cases, may play a role in the development of these tumors. Further studies are needed to fully understand the contributions of histopathologic and immunohistochemical factors to vestibular schwannoma biological activity.
Authors: Luis Lassaletta; Miguel Torres-Martín; Jesús San-Román-Montero; Javier S Castresana; Javier Gavilán; Juan Antonio Rey Journal: Eur Arch Otorhinolaryngol Date: 2012-11-21 Impact factor: 2.503
Authors: Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey Journal: Genet Res Int Date: 2012-02-20
Authors: Miguel Torres-Martin; Luis Lassaletta; Jesus San-Roman-Montero; Jose M De Campos; Alberto Isla; Javier Gavilan; Barbara Melendez; Giovanny R Pinto; Rommel R Burbano; Javier S Castresana; Juan A Rey Journal: Int J Oncol Date: 2013-01-24 Impact factor: 5.650
Authors: Jordina Rincon-Torroella; M Harrison Snyder; Deepa J Galaiya; Meaghan Morris; Jon D Weingart; C Matthew Stewart Journal: World Neurosurg Date: 2021-06-26 Impact factor: 2.210